Déjà vu for Bristol Myers as it faces another anti-competition lawsuit over blockbuster Pomalyst
Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect its monopoly on multiple myeloma medicine Pomalyst, BMS is back in court, facing similar allegations from insurance giant Cigna over its strategy with the same treatment.
Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect its monopoly on multiple myeloma medicine Pomalyst, BMS is back in court, facing similar allegations from insurance giant Cigna over its strategy with the same treatment.
